Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Immunotherapy
|
March 15, 2018
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program
Reynold A Panettieri, Millie Wang, Martin Braddock, et al.
Respiratory Research
|
October 22, 2020
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Andrew Menzies-Gow, Sandhia Ponnarambil, John Downie, et al.
Respiratory Medicine
|
November 14, 2025
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS
Mehul Patel, Jonathan Marshall, Fernando J Martinez, et al.
BMC Pulmonary Medicine
|
July 19, 2019
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
Mattis Gottlow, David J Svensson, Ilya Lipkovich, et al.
The Lancet. Respiratory Medicine
|
May 25, 2018
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, et al.
Respiratory Research
|
May 9, 2025
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β<sub>2</sub>-agonist: post-hoc analyses of KRONOS
Dave Singh, Mona Bafadhel, Niki Arya, et al.
Respiratory Research
|
August 5, 2024
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, et al.
ERJ Open Research
|
December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOS
John R Hurst, Dave Singh, Fernando J Martinez, et al.
Respiratory Research
|
October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
Claire Emson, Sarah Diver, Latifa Chachi, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 18, 2024
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
Shigeo Muro, Munehiro Seki, John R Hurst, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Immunotherapy
|
March 15, 2018
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program
Reynold A Panettieri, Millie Wang, Martin Braddock, et al.
Respiratory Research
|
October 22, 2020
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Andrew Menzies-Gow, Sandhia Ponnarambil, John Downie, et al.
Respiratory Medicine
|
November 14, 2025
Frequent productive cough in COPD relates to exacerbation risk and treatment benefit from budesonide/glycopyrrolate/formoterol fumarate: a post hoc analysis of KRONOS
Mehul Patel, Jonathan Marshall, Fernando J Martinez, et al.
BMC Pulmonary Medicine
|
July 19, 2019
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma
Mattis Gottlow, David J Svensson, Ilya Lipkovich, et al.
The Lancet. Respiratory Medicine
|
May 25, 2018
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, et al.
Respiratory Research
|
May 9, 2025
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β<sub>2</sub>-agonist: post-hoc analyses of KRONOS
Dave Singh, Mona Bafadhel, Niki Arya, et al.
Respiratory Research
|
August 5, 2024
Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, et al.
ERJ Open Research
|
December 17, 2025
Short-acting β<sub>2</sub>-agonist use, exacerbation risk and triple therapy in COPD: <i>post hoc</i> analyses of ETHOS
John R Hurst, Dave Singh, Fernando J Martinez, et al.
Respiratory Research
|
October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
Claire Emson, Sarah Diver, Latifa Chachi, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 18, 2024
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
Shigeo Muro, Munehiro Seki, John R Hurst, et al.
Page
of 3